Pharmacology of HIV integrase inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 01 Sep 2012 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Current Opinion in HIV and AIDS, volume 7, pages 390-400 (issn: 1746-630X,

Copyright policy )

Authors: Jessica L, Adams; Benjamin N, Greener; Angela D M, Kashuba;

doi: 10.1097/coh.0b013e328356e91c , 10.17615/788x-7393

pmid: 22789987

pmc: PMC3657291

Pharmacology of HIV integrase inhibitors

- Summary
- Subjects
- Metrics

Abstract

The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).

Related Organizations

UNC Lineberger Comprehensive Cancer Center
United States
University of North Carolina at Chapel Hill
United States

Keywords

Pyridones, HIV Infections, Quinolones, Piperazines, Pyrrolidinones, United States, Raltegravir Potassium, Oxazines, HIV-1, Humans, HIV Integrase Inhibitors, Heterocyclic Compounds, 3-Ring

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	46
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%